Generate Biomedicines (NASDAQ:GENB) Sets New 1-Year Low – Here’s What Happened

Shares of Generate Biomedicines Inc (NASDAQ:GENB – Get Free Report) hit a new 52-week low during trading on Tuesday. The company traded as low as $10.26 and last traded at $10.3350, with a volume of 59,181 shares trading hands. The stock had previously closed at $10.49.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Weiss Ratings cut Generate Biomedicines from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. HC Wainwright restated a “buy” rating on shares of Generate Biomedicines in a research note on Friday, October 30th. Finally, Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $26.40.

View Our Latest Analysis on GENB

Generate Biomedicines Stock Down 4.8%

The firm’s 50 day simple moving average is $14.23 and its 200 day simple moving average is $14.09. The company has a market cap of $1.28 billion and a price-to-earnings ratio of -6.21.

Generate Biomedicines (NASDAQ:GENB – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.18). The firm had revenue of $4.22 million during the quarter. Analysts anticipate that Generate Biomedicines Inc will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Braidwell LP bought a new position in Generate Biomedicines in the 2nd quarter valued at about $55,398,000. Banque Pictet & Cie SA bought a new stake in shares of Generate Biomedicines during the 3rd quarter worth about $26,631,000. State Street Corp bought a new stake in shares of Generate Biomedicines during the 2nd quarter worth about $8,883,000. Goldman Sachs Group Inc. acquired a new stake in shares of Generate Biomedicines in the 3rd quarter worth approximately $2,189,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Generate Biomedicines in the 2nd quarter worth approximately $1,431,000.

Generate Biomedicines Company Profile

(Get Free Report)

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

Read More

Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.